Press Releases
Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant
Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial
Debiopharm International SA initiates clinical phase II study evaluating Debio 1143 in Ovarian Cancer
FDA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of ovarian cancer
EMA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer
Debiopharm International SA presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143…
Debiopharm International SA announces results of 2 key oncology programs at 2015 AACR Conference
Debiopharm Group™ presents advances of two key oncology clinical programs at the 26th EORTC-NCI-AACR symposium in Barcelona
Debiopharm Group™ moves forward three of its oncology clinical programs and will present the recent progresses at the 50th American…